Most Clicked StoriesMore >


Hemophilia treatment from Pfizer, Spark gains FDA breakthrough status

BIO SmartBrief | Jul 25, 2016

The FDA awarded breakthrough therapy status to Pfizer and Spark Therapeutics' investigational hemophilia B gene therapy SPK-9001, a bioengineered adeno-associated virus capsid. The drug is being evaluated in a Phase I/II study as a potential one-time, intravenous treatment. PharmaTimes (U.K.) (07/22)


Janssen's multiple myeloma drug receives FDA breakthrough status

BIO SmartBrief | Jul 27, 2016

Kite gains license to allogeneic T-cell technology from UCLA

BIO SmartBrief | Jul 27, 2016

Anti-constipation tablet from Valeant, Progenics wins FDA nod

BIO SmartBrief | Jul 21, 2016

FDA fast-tracks Advaxis' adjunct therapy for cervical cancer

BIO SmartBrief | Jul 22, 2016

BIO lauds Pa. for new law on biologic interchangeability

BIO SmartBrief | Jul 26, 2016

IPO generates $75M for Kadmon

BIO SmartBrief | Jul 27, 2016

Bristol-Myers to collaborate with AbbVie on trial of lung cancer drug

BIO SmartBrief | Jul 26, 2016

Relypsa to be acquired by Galenica in $1.53B deal

BIO SmartBrief | Jul 22, 2016

Chugai, Galderma sign license deal for skin disorder treatment

BIO SmartBrief | Jul 25, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the 2016 BIO Latin America Conference

BIO SmartBrief | Jul 28, 2016

Save on shipping with FedEx®

BIO SmartBrief | Jul 28, 2016

Secure document sharing services optimized for life science

BIO SmartBrief | Jul 27, 2016

Save with UniFirst

BIO SmartBrief | Jul 26, 2016

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Jul 26, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more